Open AccessWeekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma
Author(s) -
Min Young Lee,
Ki Sun Jung,
Hae Su Kim,
Ji Yun Lee,
Sung Hee Lim,
Moonjin Kim,
Hyun Ae Jung,
Sung Min Kim,
Jong Mu Sun,
Myung Ju Ahn,
Jeeyun Lee,
Se Hoon Park,
Seong Yoon Yi,
In Gyu Hwang,
Sang Cheol Lee,
Hee Kyung Ahn,
Do Hyoung Lim,
Soon Il Lee,
Keon Woo Park
Publication year - 2015
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v21.i14.4268
Subject(s) - docetaxel , medicine , gemcitabine , febrile neutropenia , neutropenia , clinical endpoint , oncology , tolerability , pneumonitis , gastroenterology , population , phases of clinical research , adverse effect , chemotherapy , surgery , lung , clinical trial , environmental health
To assess the efficacy and safety of weekly docetaxel plus a fixed-dose rate (FDR) of gemcitabine in metastatic esophageal squamous cell carcinoma (SCC).